key: cord-0842662-9ggq0z7z authors: Brenner, Steven R. title: The potential of memantine and related adamantanes such as amantadine, to reduce the neurotoxic effects of COVID‐19, including ARDS and to reduce viral replication through lysosomal effects date: 2020-06-02 journal: J Med Virol DOI: 10.1002/jmv.26030 sha: 9016ac967dbbea55ccdb48f48c2becfef54e187a doc_id: 842662 cord_uid: 9ggq0z7z SARS-CoV-2 appears to have neurotropic aspects with neurotoxicity through interaction with ACE2 in the medullary brainstem, causing glutamate toxicity in the rostral ventrolateral medulla (RVLM), increased sympathetic tone, hypertension and pulmonary capillary leakage of fluid into the alveoli, resulting in acute respiratory distress syndrome (ARDS). Memantine, a moderate affinity, uncompetitive N-Methyl-D-aspartic acid (NMDA) receptor antagonist which prevents excess calcium entry into cells is commonly utilized in treating patients with Alzheimer's disease, and may inhibit the neurotoxicity induced by SARS-CoV-2 in the medullary brain stem to avoid development of ARDS. Memantine and related adamantine such as amantadine, which is utilized in Parkinson's disease and influenza, may have some anti-viral potential as well. Memantine and similar adamantines may have potential as repurposed medicines for treating Covid19 with inhibition of neurotoxicity, ARDS and viral replication, since Memantine appears to be lysosomotropic. This article is protected by copyright. All rights reserved. The potential of memantine and related adamantanes such as amantadine, to reduce the neurotoxic effects of COVID-19, including ARDS and to reduce viral replication through lysosomal effects To The Editor, Amantadine binds moderately with a pore formed by SARS-CoV protein E 8 and downregulates the lysosomal enzymes, Cathepsin L /B (CTSL) genes, inhibiting their activity and raising lysosomal pH, which could interfere with the lysosomal phase of SARS-CoV-2 infection. 9 Memantine is also a lysotrophic agent, 10 and could have similar effects to amantadine. Memantine, may be a consideration as treatment for COVID-19, due to interfering with the NMDA activity, inhibiting excess glutamate release in the medullary brain stem, a potential neurotoxic effect from depleted ACE2, contributing to development of ARDS, and also inhibit viral replication through potential interaction with viral E protein (related adamantane-amantadine being studied in this regard), and lysosomal function. 10 Memantine. amantadine and related adamantanes penetrate the blood-brain barrier. This is an advantage, although also a cause of potential side effects such as depression and confusion. Side effects of memantine may include constipation, headache, and hypertension as well as slow or fast heart beat, bloating and swelling of the face, arms and hands as well as feet and legs. Amantadine may cause bladder pain, confusion and swelling in the hands and feet, and inability to move the eyes. It does have effects on the nervous system and is utilized to treat levodopa-induced dyskinesia in Parkinson's disease. Side effects of these medicines may overlap with symptoms of COVID-19, since as the pandemic progresses, more patients are being seen with neurological abnormalities, such as confusion, strokes, and seizures, which would require more detailed evaluation to determine the origin of such symptoms. The neuroinvasive potential of SARS-CoV2 may be at least partially responsible for the respiratory failure of COVID-19 patients Overexpression of angiotensionconverting enzyme 2 attenuates tonically active glutamatergic input to the rostral ventrolateral medulla in hypertensive rats Angiotension-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patietns with diabetes during COVID-19 pandemic Novel treatment with neuroprotective and antiviral properties against a neuroinvasive human respiratory virus Memantine can relieve the neuronal impairment caused by neurotropic virus infection N-methyl-d-aspartate (NMDA) receptor blockade prevents neuronal death induced by Zika virus infection Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment Conductance and amantadine binding of a pore formed by a lysineflanked transmembrane domain of SARS coronavirus envelope protein Amantadine disrupts lysosomal gene expression; potential therapy for COVID19 Evidence for lysosomotropism of memantine in cultured human cells: cellular kinetics and effects of memantine on phospholipid content and composition, membrane fluidity and beta-adrenergic transmission The author declare that there is no conflict of interest.